WHO-led trial is studying three anti-inflammatory drugs as potential COVID-19 treatments
A trial led by the World Health Organization is testing three anti-inflammatory drugs - artesunate, imatinib and infliximab- as potential treatments for COVID-19. (Source: the Mail online | Health)
Source: the Mail online | Health - August 12, 2021 Category: Consumer Health News Source Type: news
Certain Biologics May Boost Infection Risk in Psoriasis Patients Certain Biologics May Boost Infection Risk in Psoriasis Patients
Psoriasis patients who are new users of infliximab and adalimumab appear to be at a greater risk of serious infection than those beginning therapy with etanercept, according to French researchers.Reuters Health Information (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - August 2, 2021 Category: Infectious Diseases Tags: Dermatology News Source Type: news
Johnson & Johnson Reports Q2 2021 Results
New Brunswick, N.J. (July 21, 2021) – Johnson & Johnson (NYSE: JNJ) today announced results for second-quarter. “Our second-quarter results showcase Johnson & Johnson’s diversified portfolio, driven by strong sales and earnings growth across our Medical Device, Consumer Health and Pharmaceutical businesses,” said Alex Gorsky, Chairman and Chief Executive Officer. “I’m so proud of our 136,000 colleagues who remain focused on delivering our medicines and products to patients and consumers around the world, in addition to advancing our pipeline with new product launches and regulatory submissions. These ac...
Source: Johnson and Johnson - July 21, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news
Ustekinumab in Infliximab-refractory Pediatric UC Ustekinumab in Infliximab-refractory Pediatric UC
This study evaluated the efficacy of ustekinumab following failure of prior biologics in pediatric ulcerative colitis.Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 23, 2021 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news
New Phase 3b Psoriatic Arthritis (PsA) Data Show First-in-Class TREMFYA ® (guselkumab) Achieved Robust Joint Symptom Improvement and Complete Skin Clearance in Patients with Inadequate Response to Tumor Necrosis Factor Inhibition (TNFi-IR)
SPRING HOUSE, PENNSYLVANIA, June 2, 2021 – Today the Janssen Pharmaceutical Companies of Johnson & Johnson announced new efficacy and safety data for first-in-class TREMFYA® (guselkumab), including data from the first study evaluating a selective IL-23 inhibitor in adult patients with active PsA, all of whom had demonstrated inadequate response or intolerance to TNFi.1 In the COSMOS Phase 3b study, significantly higher proportions of patients treated with TREMFYA showed joint symptom improvement and complete skin clearance versus placebo at week 24 in this true TNFi-IRa patient population, which is often more diffic...
Source: Johnson and Johnson - June 2, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Avsola (Infliximab-axxq for Injection) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - June 1, 2021 Category: Drugs & Pharmacology Source Type: news
Avsola (infliximab-axxq)
Title: Avsola (infliximab-axxq)Category: MedicationsCreated: 5/28/2021 12:00:00 AMLast Editorial Review: 5/28/2021 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - May 28, 2021 Category: Drugs & Pharmacology Source Type: news
Infliximab May Reduce Immunogenicity to SARS-CoV-2 Vaccine
TUESDAY, May 18, 2021 -- Individuals with inflammatory bowel disease who are treated with infliximab rather than vedolizumab have reduced immunogenicity to a single dose of BNT162b2 and ChAdOx1 nCoV-19 severe acute respiratory syndrome coronavirus 2... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 18, 2021 Category: Pharmaceuticals Source Type: news
Double Switching From Infliximab to Biosimilars in IBD Double Switching From Infliximab to Biosimilars in IBD
Does double switching from infliximab to the biosimilars CT-P13 and then to SB2 impair the effectiveness, immunogenicity or safety of anti-TNF therapy?Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 21, 2021 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news
Johnson & Johnson Reports 2021 First-Quarter Results
New Brunswick, N.J. (April 20, 2021) – Johnson & Johnson (NYSE: JNJ) today announced results for first-quarter 2021. “Johnson & Johnson delivered a strong first quarter performance led by the above market growth of our Pharmaceutical business and continued recovery in Medical Devices,” said Alex Gorsky, Chairman and Chief Executive Officer. “The ability to deliver these results while simultaneously advancing our robust pipeline of life-enhancing medicines, products and solutions during these times is a testament to the strength and resilience of our business and the dedication of the 135,000 employees of Jo...
Source: Johnson and Johnson - April 20, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news
Researchers Urge Second COVID Vaccine Dose for Infliximab Users Researchers Urge Second COVID Vaccine Dose for Infliximab Users
Patients being treated with infliximab had weakened immune responses to the first dose of the Pfizer and AstraZeneca COVID vaccines compared with patients on vedolizumab, according to a new UK study.Medscape Medical News (Source: Medscape Infectious Diseases Headlines)
Source: Medscape Infectious Diseases Headlines - April 7, 2021 Category: Infectious Diseases Tags: Infectious Diseases News Source Type: news
Infliximab Weakens COVID Antibody Response for Patients With IBD Infliximab Weakens COVID Antibody Response for Patients With IBD
Although anti-tumor necrosis factor (anti-TNF) drugs are routinely used for patients with IBD, the impact of their immune-suppressing properties on protective immunity to COVID-19 is unknown.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - March 25, 2021 Category: Gastroenterology Tags: Gastroenterology News Source Type: news
Infliximab May Impede Serologic Response to SARS-CoV-2
TUESDAY, March 23, 2021 -- For patients with inflammatory bowel disease (IBD), infliximab is associated with attenuated serological responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), according to a study published online... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 23, 2021 Category: Pharmaceuticals Source Type: news
Common inflammatory bowel disease treatment linked to reduced COVID-19 antibody response
(University of Exeter) The findings arose from the CLARITY study, which recruited 6,935 patients with Crohn's disease and ulcerative colitis from 92 UK hospitals between September and December 2020. It found that fewer than half of people with IBD who were treated with infliximab had detectable antibodies after SARS-CoV-2 infection, the coronavirus that causes COVID-19. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - March 22, 2021 Category: Infectious Diseases Source Type: news
Egis Pharmaceuticals PLC Announces Registration of the First...
Egis Pharmaceuticals PLC (Egis) received the CE In Vitro Diagnostic (IVD) Medical Device Certificate of its PREDYSTIC® Infliximab RA Kit on December 21st, 2020.(PRWeb March 16, 2021)Read the full story at https://www.prweb.com/releases/egis_pharmaceuticals_plc_announces_registration_of_the_first_blood_based_ce_ivd_precision_medicine_tool_for_therapy_selection_in_rheumatoid_arthritis/prweb17793650.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - March 16, 2021 Category: Pharmaceuticals Source Type: news
